Allergic and nonallergic delayed infusion reactions during natalizumab therapy

Archives of Neurology

Volumn 65, Issue 5, 2008, Pages 656-658

  Hellwig, Kerstin ^a   Schimrigk, Sebastian ^a   Fischer, Malte ^a   Haghikia, Aiden ^a   Müller, Thomas ^a   Chan, Andrew ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; NECK PAIN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RASH;

ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 43549089971     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.5.656     Document Type: Article

References (11)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
2. Phillips JT, O'Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006;67(9):1717-1718.
3. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19-31.
4. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41-44.
5. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97(6):1408-1414.
6. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol. 2006;135(2):147.
7. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15-23.
8. Krumbholz M, Pellkofer H, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64(9):1331-1333.
9. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98(6):1315-1324.
10. Persley KM. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis. 2004;10(1):62-63.
11. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743-747.